Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
European Journal of Surgical Oncology Dec 06, 2017
Julião GPS, et al. - In this study, researchers performed comparison of surgery-free and distant-metastases free survival among cT3 rectal cancer patients undergoing standard or extended neoadjuvant chemoradiation (nCRT). They observed that dose-escalation and consolidation chemotherapy were insufficient to improve long-term surgery-free survival among cT3 rectal cancer patients and provided no advantage in distant metastases-free survival.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
